Роль иммунного микроокружения в развитии рака молочной железы

Abstract

Traditionally, breast cancer has not been considered as a typical immunogenic tumor type. Nevertheless, it is well known that breast cancer is a heterogeneous mixture of different molecular subtypes and infiltration of tumor tissue by immunocompetent cells is associated with response to chemotherapy and survival in a certain molecular subtypes of breast cancer. Analysis of works of various research groups suggests that, immune markers, such as the presence of CD8 + lymphocytes, T regulatory cells in the tumor, as well as the ratio of CD8/CD4T should be used to stratify risk groups with prognostically unfavorable types of breast cancer as well as use as a factor in predicting the effectiveness of anti-HER2 therapy and chemotherapy for triple negative and HER2-overexpressing breast cancer subtypes.